BioCryst Pharmaceuticals
 |
|
| Public (NASDAQ: BCRX) | |
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Durham, North Carolina, USA |
|
Key people
|
Jon P. Stonehouse , President and Chief Executive Officer Thomas Staab II, Chief Financial Officer |
| Products | Biotechnology |
| Revenue |
 US$26.3M (FY 2012)
|
 US$-33.9M (FY 2012)
|
|
|
US$-39.1M (FY 2012)
|
|
| Total assets |
US$57.4M (FY 2012)
|
| Total equity |
US$-0.4M (FY 2012)
|
|
Number of employees
|
37 (2013) |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Durham, North Carolina. The company focuses on orphan & autoimmune diseases, and antivirals. The company's most advanced drug candidate is the antiviral Peramivir, which is approved in Japan, Korea and China. It was authorized by the FDA for emergency use in the treatment of patients hospitalized with influenza during the 2009-10 influenza A virus subtype H1N1 pandemic.
The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.
BioCryst is a member of the Alliance for Biosecurity, a group of companies that work to develop vaccines and other measures that can be used in the case of a pandemic or bioterrorism attack.
...
Wikipedia